ArticleAnnals of translational medicine2019
CMTTdb: the cancer molecular targeted therapy database.
Article in Annals of translational medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- MUSTARD-a comprehensive resource of mutation-specific therapies in cancer.Database : the journal of biological databases and curation · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe cancer molecular targeted therapy has achieved unprecedented progress in the past decade and is thought to be the most promising direction for cancer treatment in future. As the fast growing of the clinical trials of targeted anticancer agents for different cancer types, it is critical to collect and integrate such information to guide clinical practice.
methodsWe constructed the Cancer Molecular Targeted Therapy database (CMTTdb) to store and retrieve molecular targeted therapy data about randomized clinical trials (RCTs) of targeted agents and also accompanied targets, biomarkers, targeted cancer subtypes, etc.
resultsDifferent with some existing resources, CMTTdb particularly focuses on clinical application of the trails. Design of the trails, such as treatment modalities (monotherapy or combination with other therapies), as well as results on clinical efficacy parameters, adverse events are also collected. In this current version, CMTTdb contains data for 1,088 clinical trials which cover 165 agents, 80 targets, 15 cancer types (95 molecular subtypes and 56 histological or cytological subtypes) from public literatures. This database is freely available at http://www.biosino.org/CMTTdb. A user-friendly web interface was designed so that these data can be easily retrieved.
conclusionsCMTTdb will be a valuable source for providing access to information of clinical trials on the rapidly growing number of novel targeted agent and be useful in guiding oncologists for the optimization of the therapy strategy for cancer treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.